Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per ...

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

The quality and compliance of the content foundation you build today helps your organization scale efficiently in the future.

The FDA has granted approval to Akeso's differentiated programmed cell death protein 1 (PD-1) monoclonal antibody, penpulimab ...

Caribou is scaling back its operations, halting multiple programmes, and cutting staff to focus on two cancer programmes.